N8-Acetylspermidine: A Polyamine Biomarker in Ischemic Cardiomyopathy With Reduced Ejection Fraction

Aditi Nayak, Emory University
Chang Liu, Emory University
Anurag Mehta, Emory University
Yi-An Ko, Emory University
Ayman S. Tahhan, Emory University
Devinder S. Dhindsa, Emory University
Karan Uppal, Emory University
Dean Jones, Emory University
Javed Butler, Emory University
Alanna Morris, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: Journal of the American Heart Association
Volume: Volume 9, Number 11
Publisher: Wiley | 2020-06-02, Pages e016055-e016055
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1161/JAHA.120.016055
Permanent URL: https://pid.emory.edu/ark:/25593/vgzgn

Final published version: http://dx.doi.org/10.1161/JAHA.120.016055

Copyright information:
© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed November 10, 2022 9:24 AM EST
N8-Acetylspermidine: A Polyamine Biomarker in Ischemic Cardiomyopathy With Reduced Ejection Fraction

Aditi Nayak, MD; Chang Liu, MPH; Anurag Mehta, MD; Yi-An Ko, PhD; Ayman S. Tahhan, MD; Devinder S. Dhindsa, MD; Karan Uppal, PhD; Dean P. Jones, PhD; Javed Butler, MD, MPH, MBA; Alanna A. Morris, MD, MSc; Arshed A. Quyyumi, MD

BACKGROUND: Patients with ischemic cardiomyopathy (ICM) have worse outcomes than those with coronary artery disease alone and those with non-ICM. N8-acetylspermidine (N8AS) is a polyamine that regulates ischemic cardiac apoptosis and resultant cardiac dysfunction. We hypothesized that N8AS is a mechanistic biomarker of adverse outcomes in patients with ICM.

METHODS AND RESULTS: High-resolution plasma metabolomics profiling and mass spectrometry were used to quantitate N8AS levels in a discovery cohort of 474 patients with coronary artery disease (age: 68±11 years, 12% black, 26% women): 154 with ICM, and 320 without ICM; and in an external validation cohort of 85 patients with ICM (age: 60±12 years, 37% black, 19% women). Patients without heart failure (HF) at baseline were followed for incident HF. The association between N8AS (log2-transformed, standardized) and outcomes of all-cause mortality and incident HF were examined using Cox regression. N8AS was higher (10.39 [interquartile range, 7.21–17.75] versus 8.29 nmol/L [interquartile range, 5.91–11.42]; \( P < 0.001 \)) in patients with ICM compared with patients who had coronary artery disease without ICM. Higher N8AS levels were associated with higher mortality in patients with ICM (hazard ratio [HR], 1.48; 95% CI, 1.19–1.85 per SD increase \( [P = 0.001] \)), independent of B-type natriuretic peptide, high-sensitivity troponin I, and high-sensitivity C-reactive protein. Findings were validated in the independent cohort. Moreover, higher N8AS level was associated with incident HF in patients without HF at baseline (HR, 4.16; 95% CI, 1.41–12.25 per SD increase \( [P = 0.01] \)).

CONCLUSIONS: Independent of traditional HF measures, higher N8AS levels are associated with higher mortality in patients with ICM and incident HF in those who have coronary artery disease without HF. N8AS is a novel mechanistic biomarker in ICM.

Key Words: biomarker ■ ischemic cardiomyopathy ■ risk prediction

While mortality associated with coronary artery disease (CAD) has declined over the past 2 decades, the incidence of heart failure (HF) attributable to CAD (ischemic cardiomyopathy [ICM]) has increased.\(^1\) ICM is the leading cause of HF with reduced ejection fraction (EF), accounting for approximately two thirds of all cases,\(^2\) and is associated with a worse prognosis compared with either CAD alone or with non-ICM (NICM).\(^3\)

Several prognostic biomarkers associated with HF have been discovered. Most of these are reflective of either HF-associated myocyte stretch (natriuretic peptides), myocardial injury or ischemia (high-sensitivity troponin), or of the final-common pathophysiology of progressive HF, regardless of the mechanism of HF development.\(^4\) In this context, a mechanistic biomarker that is upstream to the final HF phenotype may not only refine prognostication but also be a
Nayak et al

N8-Acetylspermidine in Ischemic Cardiomyopathy

**CLINICAL PERSPECTIVE**

**What Is New?**
- N8-Acetylspermidine (N8AS), a polyamine that is involved in the regulation of cardiomyocyte cell death and resultant cardiac dysfunction during ischemic injury, is a mechanistic biomarker that is upstream to the final-common heart failure (HF) phenotype.
- Patients with ischemic cardiomyopathy (ICM) have higher N8AS levels than those with coronary artery disease without HF, or non-ICM.
- Independent of traditional biomarkers, higher circulating N8AS levels are associated with higher mortality in patients with ICM in 2 independent cohorts and also with greater risk of incident HF in patients who have coronary artery disease without HF.

**What Are the Clinical Implications?**
- A mechanistic biomarker that is upstream to the final HF phenotype may not only help refine prognostication but may also be a potential therapeutic target. In this context, N8AS is a novel mechanistic biomarker of ischemic cardiomyocyte death and resultant cardiac dysfunction.
- Independent of B-type natriuretic peptide, high-sensitivity troponin I, and high-sensitivity C-reactive protein, higher circulating N8AS is associated with higher mortality in patients with ICM and greater risk of incident HF in patients who have coronary artery disease without HF.
- Future studies should examine whether N8AS is a “modifiable” risk factor in ICM by examining the effect of modulation of polyamine levels by diet and pharmacological therapy on disease progression.

---

**Nonstandard Abbreviations and acronym**

| Acronym | Description |
|---------|-------------|
| ACEI    | angiotensin-converting enzyme inhibitor |
| ARB     | angiotensin receptor blocker |
| BNP     | B-type natriuretic peptide |
| CAD     | coronary artery disease |
| EF      | ejection fraction |
| HF      | heart failure |
| HMDB    | Human Metabolome Database |
| HR      | hazard ratio |
| hsCRP   | high-sensitivity C-reactive protein |
| hsTnI   | high-sensitivity troponin I |
| ICM     | ischemic cardiomyopathy |

---

potential therapeutic target. Cardiac dysfunction in CAD is a complex process characterized by myocyte apoptosis and autophagy caused by both ischemia and ischemia/reperfusion injury. Polyamines, including spermidine and its derivatives, are aliphatic molecules that modulate the cardiac stress response to ischemia by regulating cardiomyocyte apoptosis and autophagy. Intracellular spermidine is catabolized by the enzyme spermidine N8-acetyltransferase to N8-acetylspermidine (N8AS). N8AS is then excreted from the cell, and is therefore a plasma indicator of intracellular polyamine activity. We have previously demonstrated reliable quantification of plasma N8AS concentrations using high-resolution metabolomics profiling followed by reference standardization. Prior preclinical studies have established a key regulatory role for polyamines in cardiomyocyte cell death during the ischemic cascade as well as HF development. Pharmacological polyamine depletion has been shown to protect cardiomyocytes from ischemia-induced apoptosis. However, there is a paucity of data on the translation of these findings to the use of polyamines as prognostic biomarkers in this population.

The purpose of our study was to investigate the association between plasma N8AS levels and progression of ICM. Our hypothesis was that: (1) N8AS levels will be higher in patients with ICM compared with those who have CAD without ICM and those with NICM; and (2) higher levels of N8AS, reflective of increased polyamine turnover and resultant cardiomyocyte death during ischemia will predict (a) adverse outcomes in ICM and (b) incident HF in those without HF. Prediction of adverse events was explored in a discovery cohort and replicated in an independent validation cohort. We further investigated whether the predictive capacity of N8AS was independent of BNP (B-type natriuretic peptide), high-sensitivity troponin I (hsTnI), and hsCRP (high-sensitivity C-reactive protein). Finally, using targeted and global metabolomics analyses, we investigated metabolic pathways that are associated with N8AS.
METHODS

Study Population

Discovery Cohort

We studied patients with CAD (defined as a history of myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, or an index left heart catheterization showing ≥50% stenosis in at least 1 major epicardial vessel) undergoing cardiac catheterization who were enrolled in the Emory Cardiovascular Biobank at 3 Emory Healthcare sites between 2003 and 2008. Participants were interviewed to collect information about demographic characteristics, medical history, and behavioral habits as previously described. CAD severity was evaluated using the modified Duke CAD Index with ≥50% stenosis classified as clinically significant. Echocardiographic left ventricular EF was abstracted after reviewing medical records. Medical records and International Classification of Diseases, Ninth Revision (ICD-9) diagnostic codes were reviewed to confirm self-reported medical history.

Patients who had HF with preserved EF (defined as a history of HF at enrollment and EF ≥50%) were excluded. Prevalent ICM was defined as the presence of physician diagnosis of HF or ICD-9 discharge diagnosis of HF and EF <50%, or EF <50% at the time of study enrollment.

Validation Cohort

Patients from the Atlanta Cardiomyopathy Consortium, a prospective cohort study that enrolled outpatients who had HF with reduced EF (EF <50%) from 3 Emory University–affiliated hospitals in the greater metropolitan Atlanta area from 2007 to 2011, constituted the external validation cohort. Findings in the discovery cohort were validated in patients with ICM from this cohort. As a secondary analysis, we compared patients who had ICM with those who had NICM in the validation cohort.

All participants provided written informed consent at the time of enrollment, and both studies were approved by the institutional review board at Emory University, Atlanta, GA. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Follow-Up and Outcomes

Study participants were prospectively followed for the primary outcome of all-cause mortality and the secondary end point of HF hospitalization. Outcome censoring was performed on October 15, 2018. Follow-up data were obtained by annual phone contact, electronic medical record review, data from the social security death index, and state records. Incident HF was defined as the absence of a documented history of HF and EF >50% at study enrollment, and HF hospitalization during follow-up.

High-Resolution Metabolomics for Metabolic Profiling

High-resolution metabolomics was performed using established methods. All patients underwent an overnight fast before blood collection. Plasma specimens were collected before catheterization and stored at −80°C. Samples were extracted and analyzed as previously described. Briefly, extractions were performed with acetonitrile containing a mixture of internal standards and maintained in an autosampler at 4°C until injection. Each sample was analyzed using a Thermo LTQ Velos Orbitrap high-resolution (60 000 mass resolution) mass spectrometer (Thermo Fisher Scientific) and C18 column chromatography. For the validation cohort, samples were analyzed using liquid chromatography–Fourier transform mass spectrometry (Accela-LTQ Velos Orbitrap; mass-to-charge ratio [m/z] range from 85 to 850 ppm) with 10-uL injection volume using a dual chromatography setup (anion exchange and HILIC C18) and a formic acid/acetonitrile gradient. Electrospray ionization was used in the positive ion mode. Data were extracted using apLCMS with modifications by xMSanalyzer as m/z features, where an m/z feature is defined by m/z, retention time, and ion intensity (integrated ion intensity for the chromatographic peak). Metabolite annotation was performed using xMSannotator v1.3.2 using Human Metabolome Database (HMDB) v3.6. Identity of N8AS was previously confirmed via tandem mass spectrometry (MS/MS) and matching fragmentation pattern and retention time with the authentic standard.

Quantification of N8AS

In the discovery cohort, quantification of N8AS was accomplished using a reference standardization protocol using NIST SRM 1950 and a pooled reference plasma analyzed with each batch (“Q standard”) as previously described. Based on triplicate analysis of the Q standard, the concentration of N8AS within the Q standard was determined to be 5.62±1.92 nmol/L. In the validation cohort, N8AS was reported as feature intensities.

Biomarker Measurements

Levels of BNP (ARCHITECT BNP chemiluminescent microparticle immunoassay, Abbott Laboratories, reported in pg/mL), hsTnI (ARCHITECT STAT High Sensitive Troponin-I chemiluminescent microparticle immunoassay, Abbott Laboratories, reported in pg/mL), and hsCRP (MULTIGENT CRP Vario latex
immunoassay, Abbott Laboratories, reported in mg/L) were measured as previously described.\textsuperscript{20,21}

**Metabolome-Wide Association Study of N8AS**

All metabolite features were measured in triplicates, and median intensities were taken from the nonzero readings. Features with >20% zero readings were excluded. Metabolome-wide association study of N8AS was then performed using Spearman rank-based correlation to determine metabolites that significantly correlated with N8AS using false discovery rate <0.01 (Benjamini and Hochberg method, denominator: 5719 detectable features).\textsuperscript{22} These metabolites were selected for pathway enrichment analysis in Mummichog (version 2.0.6).\textsuperscript{23} Identities of many of the m/z features are known from previous research using ion dissociation patterns by MS/MS, coelution with authentic standards, and cross-platform validation.\textsuperscript{11,17,19} Possible identities of other m/z features were obtained using the METLIN Mass Spectrometry Database,\textsuperscript{24} HMDB,\textsuperscript{25} and Kyoto Encyclopedia of Genes and Genomes (KEGG).\textsuperscript{26} Metabolite identification levels\textsuperscript{27} were assigned by comparison with the in-house library of confirmed metabolites, which includes metabolites confirmed using MS/MS and retention time with authentic standards (level 1), comparison of MS/MS with experimental spectra in online databases or in silico predicted spectra (level 2), annotation at the metabolite class level (level 3), medium or high confidence databases matches from xMSannotator (level 4), and accurate mass match (level 5).

**Targeted Network and Pathway Analysis**

KEGG\textsuperscript{26} Mapper was used to target polyamine metabolism. Matches to adducts for metabolites in pathways associated with polyamine metabolism were selected using HMDB\textsuperscript{25} and KEGG.\textsuperscript{26} Correlation of metabolites with N8AS was determined as previously described.

**Statistical Analysis**

Data are presented as mean±SD, median (interquartile range), or number (percentage) of patients. Baseline characteristics were compared between groups using Student t test or ANOVA for normally distributed continuous variables, Mann–Whitney U for Kruskal–Wallis test for non-normally distributed continuous variables, and chi-square test for categorical variables.

N8AS levels were log\textsubscript{2}-transformed and standardized (expressed per 1 SD; z score) for all analyses. Cox proportional hazards models were used to determine the association of N8AS with outcomes, adjusted for age, sex, race, creatinine, body mass index, smoking history, diagnosis of diabetes mellitus, hypertension, and hyperlipidemia; with and without inclusion of other biomarkers (BNP, hsTnI, and hsCRP) in the models. We used Schoenfeld residuals to check the proportional hazards assumption and found no evidence of violation. Less than 10% of patients had missing biomarker data, and available case analysis was performed. \textit{P}<0.05 was considered statistically significant.

Data were analyzed using SAS statistical software version 9.4 (SAS Institute Inc) and R statistical software (version 3.5.1, R Foundation for Statistical Computing).

**RESULTS**

**Baseline Characteristics: Discovery Cohort**

The discovery cohort consisted of 474 patients with CAD (mean age: 67.7±11.0 years; 25.9% women, 11.8% black), 320 without ICM, and 154 with ICM (Table 1). Risk factor profile was similar in those with and without ICM, but levels of BNP, hsTnI, and hsCRP were higher in patients with ICM. Patients with ICM had higher levels of N8AS than those without ICM (ICM: 10.39 [7.21–17.75] nmol/L; no ICM: 8.29 [5.91–11.42] nmol/L [\textit{P}<0.001]). There was a similar variation in log\textsubscript{2}-transformed, standardized N8AS levels (ICM: 0.23±0.56; no ICM: −0.11±1.14 [\textit{P}<0.001]). A modest correlation was observed between N8AS levels and BNP (r=0.40, \textit{P}<0.001) and hsCRP (r=0.26, \textit{P}<0.001), but not with hsTnI levels (r=0.07, \textit{P}=0.14).

Elevated N8AS levels (per 1-SD increase in log\textsubscript{2}-transformed, standardized N8AS) were independently associated with higher risk of ICM (adjusted odds ratio, 2.97; 95% CI, 1.94–4.54 [\textit{P}<0.001]).

**N8AS Levels and Cardiovascular Outcomes in ICM: Discovery Cohort**

During a median follow-up of 3.4 (interquartile range, 1.6–6.3) years, there were 109 (70.1%) all-cause death events and 62 (40.2%) HF hospitalizations in patients with ICM. Elevated N8AS levels (per 1-SD increase in log\textsubscript{2}-transformed, standardized N8AS) were independently associated with greater mortality (adjusted hazard ratio [HR], 1.48; 95% CI, 1.19–1.85 [\textit{P}=0.001]) and higher risk for HF hospitalization (adjusted HR, 1.72; 95% CI, 1.27–2.33 [\textit{P}<0.001]), independent of BNP, hsTnI, and hsCRP (Table 2, Figure 1).

**Incremental Prognostic Value to BNP**

In a multivariate model including all aforementioned covariates, together with BNP and N8AS, both were
independent predictors of events. When stratified by BNP (high BNP: >100 pg/mL) and N8AS (high N8AS: >median) levels, patients with high levels of both biomarkers had the highest risk, patients with low levels of both biomarkers had the lowest risk, and patients with elevation of only 1 biomarker had intermediate risk of all-cause mortality and HF hospitalizations (Table S1, Figure 2).

### N8AS Levels and Cardiovascular Outcomes in ICM: Validation Cohort

The external validation cohort consisted of 85 patients with ICM (mean age: 60.3±11.6 years; 18.8% women, 36.5% black) (Table S2). Patients in the validation cohort were younger, more likely to be black and receive β-blockers, less likely to smoke, and had a lower left ventricular EF than patients with ICM in the discovery cohort. All other baseline characteristics were comparable.

During a median follow-up of 6.2 years (interquartile range, 3.3–9.3 years), there were 34 (40.0%) all-cause deaths. Similar to the discovery cohort, elevated N8AS levels (per 1-SD increase in log2-transformed, standardized N8AS) were associated with higher mortality in the validation cohort (adjusted HR, 1.97; 95% CI, 1.08–3.60 \(P=0.03\)). The association between N8AS and mortality was independent of BNP levels (adjusted HR, 2.30; 95% CI, 1.19–4.44 \(P=0.01\)).

### N8AS Levels and Incident HF

Of the discovery cohort of patients with CAD without HF at the time of enrollment (n=320), 22 (6.9%) developed incident HF during a median follow-up of 6.1 years (interquartile range, 2.8–9.3 years). Patients with incident HF had a similar risk factor profile compared with those who did not, but levels of BNP were higher in patients who developed incident HF (Table S3). Elevated N8AS levels (per 1-SD increase in log2-transformed, standardized N8AS) were independently associated with higher risk of incident HF (adjusted HR, 2.30; 95% CI, 1.19–4.44 \(P=0.01\)).

---

**Table 1. Baseline Characteristics of Participants in the Discovery Cohort**

| Demographic data | CAD/No ICM (n=320) | Prevalent ICM (n=154) | \(P\) Value |
|------------------|--------------------|-----------------------|-------------|
| Age, y           | 67.44±10.77        | 68.32±10.50           | 0.40        |
| Male sex         | 234 (73.1)         | 117 (76.0)            | 0.51        |
| Black race       | 35 (10.9)          | 21 (13.6)             | 0.39        |

**Clinical data**

|                  | CAD/No ICM (n=320) | Prevalent ICM (n=154) | \(P\) Value |
|------------------|--------------------|-----------------------|-------------|
| Diabetes mellitus| 124 (38.8)         | 72 (46.8)             | 0.10        |
| Hypertension     | 230 (71.9)         | 105 (68.2)            | 0.41        |
| Hyperlipidemia   | 225 (70.3)         | 100 (64.9)            | 0.24        |
| Smoking history  | 216 (67.5)         | 107 (69.5)            | 0.67        |
| Body mass index, kg/m² | 28.78±5.08  | 28.24±4.82            | 0.27        |
| Serum creatinine, mg/dL | 1.30±0.79   | 1.35±0.68             | 0.60        |
| Ejection fraction, % | 56.31±6.24  | 30.31±9.92            | <0.001      |

**Medication history**

|                  | CAD/No ICM (n=320) | Prevalent ICM (n=154) | \(P\) Value |
|------------------|--------------------|-----------------------|-------------|
| ACEI/ARB         | 215 (67.2)         | 116 (75.3)            | 0.07        |
| β-Blocker        | 245 (76.6)         | 125 (81.2)            | 0.26        |

**Biomarkers**

|                  | CAD/No ICM (n=320) | Prevalent ICM (n=154) | \(P\) Value |
|------------------|--------------------|-----------------------|-------------|
| BNP, pg/mL       | 98.10 [47.08–206.78] | 325.40 [125.60–739.38] | <0.001      |
| hsTnI, pg/mL     | 6.90 [3.60–17.60]  | 20.75 [9.10–72.98]    | <0.001      |
| hsCRP, mg/L      | 3.10 [1.20–7.45]   | 5.35 [2.03–10.00]     | 0.001       |

**Table 2. HR Estimates for the Association Between N8AS Levels (Log2-Transformed, Standardized), All-Cause Mortality, and HF Hospitalizations in Patients With ICM**

| Discovery Cohort | All-Cause Mortality* \(HR (95\% \text{ CI})\) \(P\) Value | HF Hospitalization* \(HR (95\% \text{ CI})\) \(P\) Value |
|------------------|---------------------------------------------------------|-----------------------------------------------------------|
| Unadjusted (n=154) | 1.54 (1.26–1.87) <0.001 | 1.54 (1.19–2.01) \(P=0.001\) |
| Model 1 (n=154) | 1.48 (1.19–1.85) \(P=0.001\) | 1.72 (1.27–2.33) \(P<0.001\) |
| Model 1+BPN (n=144) | 1.39 (1.11–1.75) \(P=0.005\) | 1.62 (1.17–2.24) \(P=0.004\) |
| Model 1+hsTnI (n=152) | 1.45 (1.16–1.81) \(P=0.001\) | 1.71 (1.26–2.32) \(P=0.001\) |
| Model 1+hsCRP (n=152) | 1.43 (1.14–1.79) \(P=0.002\) | 1.66 (1.22–2.25) \(P=0.001\) |
| Model 1+BPN+hsTnI+hsCRP (n=142) | 1.34 (1.06–1.69) \(P=0.01\) | 1.56 (1.13–2.16) \(P=0.008\) |

BNP indicates B-type natriuretic peptide (in pg/mL); HF, heart failure; hsCRP, high-sensitivity C-reactive protein (in mg/L); hsTnI, high-sensitivity troponin I (in pg/mL); ICM, ischemic cardiomyopathy; and N8AS, N8-acetylspermidine.

*Hazard ratios (HRs) were calculated with the use of Cox regression models incorporating covariates listed in the table.

Model 1 adjusted for age, sex, race, creatinine, presence of diabetes mellitus, hypertension, hyperlipidemia, body mass index, and smoking history.
HR, 4.16; 95% CI, 1.41–12.25 [P=0.01]), independent of BNP, hsTnI, and hsCRP (Table 3).

N8AS Levels and NICM

To explore the effect of Etiology on N8AS levels, we performed a secondary analysis comparing patients who had NICM (n=131) with those who had ICM (n=85) in the validation cohort. Patients with ICM had higher N8AS (log2-transformed, standardized) levels (ICM: 0.18±0.1; NICM: −0.12±1.09 [P=0.02]) but similar levels of BNP (P=0.10) (Table S4). There was a significant Etiology*N8AS interaction in the prediction of all-cause mortality (P=0.02, ratio of HR in ICM:NICM per 1-SD increase in log2-transformed, standardized N8AS: 1.97). Unlike in ICM, N8AS levels (per 1-SD increase in log2-transformed, standardized N8AS) were not significantly associated with mortality in the NICM cohort (adjusted HR, 1.06; 95% CI, 0.77–1.46 [P=0.72]).

Metabolic Pathways Associated With N8AS

A total of 5719 detected features in the 474 patients in the discovery cohort entered global metabolomics analysis to determine metabolic pathways associated with N8AS. At a false discovery rate q threshold <0.01, there were 203 features that correlated with N8AS (Table S5). Pathway enrichment analysis demonstrated that these features mapped to 2 metabolic pathways: the carnitine shuttle (P=0.007) and the saturated fatty acids β-oxidation pathway (P=0.04) (Table 4).
Targeted correlation analysis of metabolites in 3 central pathways of N8AS-associated metabolism (polyamine metabolism, methionine metabolism, and urea cycle) (Figure 3) revealed 16 significant correlations at a false discovery rate $q<0.2$ (Table 4). Most urea cycle metabolites were negatively correlated, while those involved in methionine metabolism were positively correlated with N8AS.

**DISCUSSION**

The major findings of this study are: (1) N8AS levels are higher in patients with ICM compared with patients who have CAD without ICM and NICM; (2) higher circulating N8AS levels are associated with higher mortality in patients with ICM, independent of BNP; and (3) higher N8AS levels in patients who have CAD without HF are associated with greater risk of incident HF (Figure 4). N8AS levels correlate with metabolites in the carnitine shuttle and the saturated fatty acid $\beta$-oxidation pathway, as well as known pathways of N8AS-associated metabolism.

HF with reduced EF affects over 2.5 million Americans, with >50% mortality within 5 years of diagnosis. The incorporation of natriuretic peptides into clinical practice has refined prognostication in patients with HF; however, the residual risk of adverse outcomes remains high. Consequently,
with the technological evolution of high-throughput -omics platforms over the past decade, there has been a surge in the identification of new biomarkers reflective of the final-common pathophysiology of progressive HF²²: inflammation (CRP), extracellular-matrix remodeling (galectin-3), myocyte injury (troponins I and T), and myocyte stress (BNP, soluble ST2, growth differentiation factor 15).³ However, a biomarker upstream to the final-common pathway for HF, and specific to the mechanism of HF development, would likely provide additional prognostic value.⁴ Ischemic HF is a result of cardiomyocyte damage from calcium overload, oxidative stress, and activation of cellular apoptosis and autophagy occurring both during ischemia and reperfusion injury,³⁰ mechanisms unique to an ischemic pathogenesis for HF.³¹ Moreover, since no currently available therapies successfully target ischemia/reperfusion injury, which accounts for nearly 50% of the total ischemic damage to the heart,³² a biomarker specific to the ischemic cascade may also elucidate novel therapeutic targets.

Polymamines, including spermidine, spermine, and their derivatives, including N8AS, are ubiquitous aliphatic molecules with a well-recognized role in cardiac cell growth, differentiation, and protein synthesis.¹³ Specifically, they are key mediators of the ischemic cascade,³³ by regulating apoptosis or programmed cell death,⁵,⁶ and autophagy,³⁴ the principal cellular mechanisms for ischemia and reperfusion injury and subsequent cardiac failure.³⁵,³⁶ In preclinical studies, acute ischemia activates the myocardial polyamine stress response, resulting in polyamine accumulation and consequent cardiomyocyte death.⁸,³⁷ On the other hand, polyamine degradation via acetylation is enhanced during ischemia/reperfusion injury,³⁷ a reaction that also mediates ischemic apoptosis and autophagy caused by the generation of toxic metabolic products and oxidative stress.³³ Additionally, polymamines regulate nitric oxide/cGMP pathway-mediated signaling³⁸ and calcium homeostasis³⁹ during ischemia/reperfusion injury. Inhibition of the rate-limiting enzyme of polyamine biosynthesis: ornithine decarboxylase, by α-difluoromethylornithine protects cardiomyocytes from ischemia-induced apoptosis via polyamine depletion.⁸,¹²,¹³ In this study, we show that higher levels of plasma N8AS, an excretory product of intracellular spermidine that is reflective of increased polyamine turnover,⁹,¹⁰ is reproducibly associated with worse clinical outcomes in 2 independent cohorts with ICM. Moreover, we confirmed the associations between N8AS and other known polyamine-associated pathway metabolites (Figure 4). Interestingly, while the regulation of cardiomyocyte death is the principal pathophysiological role for polyamines during the ischemic cascade,³⁵,³⁶,³⁴ we did not find a correlation between N8AS and hsTnI levels in our study. However, troponin is also released from intact cells by cleavage and membrane permeability during increased cardiac metabolic demand, potentially explaining our findings.

Other clinical studies have also helped to elucidate the role of polyamines in the pathogenesis of cardiovascular disease. In a prospective analysis of 658 patients from the Bruneck study,⁷ higher dietary intake of spermidine, assessed by food questionnaires, was associated with a decreased risk of HF, as well as a composite outcome of acute coronary syndrome, stroke, and death from vascular disease. In an exploratory analysis, the authors showed inverse associations between spermidine intake and chitinase-3-like protein 1, implicated in atherosclerotic plaque inflammation and rupture, and with growth differentiation factor 15 levels, a known marker of HF progression.⁷ Two previous metabonomics studies found that higher spermidine was part of a metabolite panel that predicted the presence of HF, as well as adverse outcomes in HF, independent of BNP and galectin-3.¹⁰,⁴¹ However, since spermidine was part of a panel that also included essential amino acids, butyrylcarnitine and dimethylarginine/arginine ratio, the relative contribution of spermidine to the risk profile was not clearly elucidated. Additionally, these studies did not explore the effect of HF etiology on prognostication. We have shown that N8AS predicts outcomes in the ICM but not in the NICM population. Another novel finding of our study is that higher N8AS levels predict incident HF in patients with CAD. There is a paucity of data on

| Table 3. HR Estimates for the Association Between N8AS Levels (Log2-Transformed, Standardized) and Incident HF in Patients Who Had CAD Without HF at Baseline |
|---------------------------------|------------------------------|------------------|-----------------|
| Discovery Cohort                | Incident HF*                 | HR (95% CI)      | P Value         |
| N8AS (HR per SD Increase)       | Unadjusted (n=320)           | 5.19 (1.83–14.74) | 0.002           |
| Model 1 (n=320)                 | Model 1+BNP (n=293)          | 4.16 (1.41–12.25) | 0.01            |
| Model 1+hsTnI (n=316)           | Model 1+hsCRP (n=306)        | 3.94 (1.33–11.68) | 0.01            |
| Model 1+hsTnI+hsCRP (n=284)     | Model 1+BNP+hsTnI+hsCRP (n=284) | 4.14 (1.39–12.69) | 0.01            |

BNP indicates B-type natriuretic peptide (in pg/mL); CAD, coronary artery disease; HF, heart failure; hsCRP, high-sensitivity C-reactive protein (in mg/L); hsTnI, high-sensitivity troponin I (in pg/mL); and N8AS, N8-acetylspermidine.

*Hazard ratios (HRs) were calculated with the use of Cox regression models incorporating covariates listed in the table.

†Model 1 adjusted for age, sex, race, creatinine, presence of diabetes mellitus, hypertension, hyperlipidemia, body mass index, and smoking history.

J Am Heart Assoc. 2020;9:e016055. DOI: 10.1161/JAHA.120.016055
the use of polyamines as biomarkers for incident HF prediction. Whether increased N8AS levels reflect a decrease in intracellular spermidine bioavailability, or increased spermidine production and degradation in response to ischemic stress, requires further exploration.

**STUDY STRENGTHS AND LIMITATIONS**

The major strengths of our study include the robust confirmation and quantification of N8AS levels, as well as the validation of our findings in an independent validation cohort that utilized different mass spectrometry techniques. The use of polyamines as biomarkers for incident HF prediction provides a new perspective on the pathophysiology of ischemic cardiomyopathy. However, further studies are needed to validate these findings in larger and more diverse populations.

### Table 4. Metabolites From Global and Targeted Network and Pathway Analysis That Significantly Correlated With N8AS

| Name | m/z, Retention Time, s | Spearman Correlation Coefficient | P Value | False Discovery Rate Q Value | HMDB (Identification Level*) | Adduct |
|------|------------------------|----------------------------------|--------|-------------------------------|----------------------------|--------|
| Global metabolic pathway and network analysis | | | | | |
| Carnitine shuttle | | | | | |
| α-Linoleyl carnitine | mz422.3266_t368 | 0.17 | 1.53E-04 | 5.83E-03 | HMDB06319 (level 4) | M+H |
| Tetradecanoyl carnitine | mz372.3102_t366 | 0.22 | 1.09E-06 | 1.45E-04 | HMDB05066 (level 2) | M+H |
| L-palmitoyl carnitine | mz400.3414_t398 | 0.16 | 3.54E-04 | 9.92E-03 | HMDB00222 (level 1) | M+H |
| Trans-hexadec-2enoyl carnitine | mz398.3258_t376 | 0.20 | 7.18E-06 | 6.62E-04 | HMDB06317 (level 4) | M+H |
| Linolealoyl carnitine | mz424.3414_t384 | 0.20 | 8.17E-06 | 7.05E-04 | HMDB06461 (level 4) | M+H |
| Timnodonyl carnitine | mz468.3082_t411 | −0.17 | 1.72E-04 | 6.29E-03 | NA (level 4) | M+Na |
| Saturated fatty acids β oxidation | | | | | |
| L-palmitoylcarnitine | mz400.3414_t398 | 0.16 | 3.54E-04 | 9.92E-03 | HMDB00222 (level 1) | M+H |
| Targeted metabolic pathway and network analysis | | | | | |
| Polyamine metabolism | | | | | |
| Isoputreanine | mz161.129_t138 | 0.17 | 1.39E-04 | 5.55E-03 | HMDB06009 (level 4) | M+H |
| Methionine/cysteine metabolism | | | | | |
| L-methionine | mz172.0403_t139 | 0.21 | 2.47E-06 | 2.83E-04 | HMDB00696 (level 4) | M+Na |
| Cystathionine ketimine | mz204.0328_t142 | 0.14 | 1.89E-03 | 0.03 | HMDB02019 (level 4) | M+H |
| Cystathionine sulfoxide | mz239.0712_t32 | 0.11 | 0.02 | 0.12 | HMDB02399 (level 4) | M+H |
| N-ornithyl-L-taurine | mz240.0994_t148 | −0.13 | 3.55E-03 | 9.92E-03 | HMDB33519 (level 4) | M+H |
| 4-Hydroxy-17β-estradiol-2-S-glutathione | mz594.249_t421 | −0.17 | 2.26E-04 | 7.58E-03 | HMDB06139 (level 4) | M+H |
| Serine | mz106.0495_t142 | 0.11 | 0.01 | 0.12 | HMDB000187; HMDB03406 (level 1) | M+H |
| Cysteinyl-cysteine | mz225.0347_t138 | 0.10 | 0.03 | 0.15 | HMDB02772 (level 4) | M+H |
| Methylmalonate | mz141.0145_t33 | 0.11 | 0.01 | 0.10 | HMDB00202 (level 4) | M+Na |
| γ-L-glutamyl-L-cysteine | mz251.0701_t374 | 0.15 | 1.07E-03 | 0.02 | HMDB01049 (level 4) | M+H |
| Urea cycle metabolism | | | | | |
| Argininosuccinic acid; N2- (3-hydroxyoxalyl)arginine; N2- (3-carboxy-2-hydroxy-1-oxopropyl) arginine | mz291.13_t1416 | −0.11 | 0.01 | 0.10 | HMDB00052; HMDB03765; HMDB39408 (level 4) | M+H |
| Hippurate | mz180.0656_t68 | 0.19 | 4.55E-05 | 2.52E-03 | HMDB00714 (level 2) | M+H |
| 4-Acetamidobutanoate | mz146.081_t147 | −0.12 | 8.93E-03 | 0.07 | HMDB03681 (level 2) | M+H |
| Peptide 2-[3-carboxy-3-(methylammonio)propyl]-L-histidine | mz294.13_t1420 | −0.12 | 8.76E-03 | 0.07 | NA | M+Na |
| Asparagine | mz133.0603_t147 | −0.12 | 9.54E-03 | 0.07 | HMDB01685 (level 1) | M+H |
| Asymmetric dimethylarginine; symmetric dimethylarginine | mz203.1503_t377 | −0.10 | 0.03 | 0.15 | HMDB01539; HMDB03334 (level 4) | M+H |

M+Na indicates sodium adduct; m/z, mass-to-charge ratio; NA, not annotated in Human Metabolome Database (HMDB); and N8AS, N8-acetylspermidine.

1. Metabolite identification levels are adapted from the criteria proposed by Schymanski et al:
   - Level 1 confirmed by tandem mass spectrometry (MS/MS) and co-elution with authentic standards
   - Level 2 confirmed by MS/MS and matches with online databases or in silico predicted spectra
   - Level 3 confirmed by MS/MS at the chemical class level, but no evidence for a specific metabolite
   - Level 4 computationally assigned annotation using xMSannotator (medium or high confidence)
   - Level 5 accurate mass match

2. For metabolites with multiple adduct matches, only the hydrogen adduct (M+H) adduct is reported here.
Limitations include the small validation cohort sample size and a lack of serial N8AS measurements. This precluded estimations of N8AS variability with acute decompensated HF.

**Figure 3.** Correlated metabolites by targeted network and pathway analysis of N8-acetylspermidine (N8AS)-related pathways.
In red: Negatively correlated with N8AS. In blue: Positively correlated with N8AS. SAM indicates S-adenosyl methionine; and SAT 1/2, spermidine/spermine acetyltransferase 1/2.

**Figure 4.** Summary of study findings.
N8-Acetylspermidine (N8AS) levels are higher in patients with ischemic cardiomyopathy (ICM) compared with patients who had coronary artery disease (CAD) without ICM (P<0.001) and non-ICM (NICM) (P=0.02). Higher circulating N8AS levels are associated with higher mortality in patients with ICM but not in patients with NICM. Higher N8AS levels in patients who have CAD without heart failure (HF) are associated with greater risk of incident HF. N8AS levels are log$_2$-transformed and standardized (expressed per 1 SD). All analyses were adjusted for age, sex, race, creatinine, presence of diabetes mellitus, hypertension, hyperlipidemia, body mass index, and smoking history.
CONCLUSIONS
Circulating N8AS levels are higher in patients with ICM compared with those who have CAD without ICM and NICM. Higher levels are predictive of mortality and HF hospitalizations in patients with ICM, and with incident HF in those without HF, independent of BNP, hsTnI, and CRP levels. Whether N8AS is a risk factor for ICM and whether the modulation of polyamine metabolism and levels via diet32 and pharmacological therapy, such as α-difluoromethylornithine,8,12,13 affect disease progression needs further investigation.

ARTICLE INFORMATION
Received January 24, 2020; accepted April 9, 2020.

Affiliations
From the Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Department of Medicine (A.N., C.L., A.M., Y.-A.K., A.S.T., D.S.D., A.A.M., A.A.Q.) and Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine (K.U., D.F.J.), Emory University School of Medicine, Atlanta, GA; Departments of Epidemiology (Y.-A.K.) and Biostatistics and Bioinformatics (Y.-A.K.), Emory University, Atlanta, GA; Division of Cardiology, University of Mississippi, Jackson, MS (J.B.).

Sources of Funding
Mehta is supported by American Heart Association grant 19POST34400057 and the Abraham J. & Phyllis Katz Foundation. Dhindsa is supported by the Abraham J. & Phyllis Katz Foundation. Morris is supported by funding from National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute K23 HL132487 and the Robert Wood Johnson Foundation (Harold Amos Medical Faculty Development Program). Quyyumi is supported by NIH grants 1P20HL113451-01, TR1HL138657-02, 1P80DK111024-03S1, 5R01HL13457-08, 3R1AAG051633-01S2, 5R01AG042127-06, 2P01HL086773-08, U54AG062334-01, 1R01HL14205-01, 5P01HL101398-02, 1P20HL13451-01, 5P01HL086773-09, 1R1AAG051633-01, R01 NS056142-01, R01 HL89650-01, HL095479-01, 1P01DK094346-01, and 2P01HL086773, and American Heart Association grant 1S5CRN23910003.

Disclosures
None.

Supplementary Materials
Tables S1–S5

REFERENCES
1. Benjamin EJ, Muntner P, Bittencourt MS. Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation. 2019;139:e65–e628.
2. Bloom MW, Greenberg B, Jaarisma T, Januzzi JL, Lam CS, Maggioni AP, Troche JN, Butler J. Heart failure with reduced ejection fraction. Nat Rev Dis Primers. 2017;3:17058.
3. de Boer RA, Daniels LB, Maisel AS, Januzzi JL Jr. State of the art: newer biomarkers in heart failure. Eur J Heart Fail. 2015;17:559–569.
4. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discovery. 2003;2:566.
5. Teringova E, Tousek P. Apoptosis in ischemic heart disease. J Transl Med. 2017;15:87.
6. Thomas T, Thomas T. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci. 2001;58:244–258.
7. Eisenberg T, Abdellatif M, Schroeder S, Primessng U, Stevko S, Pendl T, Harger A, Schipse J, Zimmermann A, Schmidt A. Cardioprotection and lifespan extension by the natural polyamine spermidine. Nat Med. 2016;22:1428.
8. Tantini B, Fiumana E, Cetrulo S, Pignatti C, Bonavita F, Shanth LM, Giordano E, Muscare C, Flamigni F, Guarracini C. Involvement of polyamines in apoptosis of cardiac myoblasts in a model of simulated ischemia. J Mol Cell Cardiol. 2006;40:775–782.
9. Casero RA Jr, Pegg AE. Spermidine/spermine n1-acetyltransferase—the turning point in polyamine metabolism. FASEB J. 1993;7:653–661.
10. Seiler N. Catabolism of polyamines. Eur J Heart Fail. 2001;58:244–258.
11. Roede JR, Uppal K, Park Y, Lee K, Tran V, Walker D, Strobel FH, Rhodes SL, Ritz B, Jones DP. Serum metabolomics of slow vs. rapid motor pro-gression Parkinson’s disease: a pilot study. PLoS One. 2013;8:e7629.
12. Cetrulo S, Tantini B, Facchini A, Pignatti C, Stefanelli C, Calderara CM, Flamigni F. A pro-survival effect of polyamine depletion on norepinephrine-mediated apoptosis in cardiac cells: role of signaling enzymes. Amino Acids. 2011;40:1127–1137.
13. Meana C, Rubin JM, Bordallo L, Suarez L, Bordallo J, Sanchez M. Correlation between endogenous polyamines in human cardiac tissues and clinical parameters in patients with heart failure. J Cell Mol Med. 2016;20:302–312.
14. Ko YA, Hayek S, Sandesara P, Tahhan AS, Quyyumi A. Cohort profile: the emory cardiovascular biobank (EMCAB). BMJ Open. 2017;7:e018753.
15. Marti CN, Georgiopoulou VV, Giamouzis G, Cole RT, Deka A, Tang WW, Dunbar SB, Smith AL, Kalogeropoulos AP, Butler J. Patient-reported selective adherence to heart failure self-care recommendations: a prospective cohort study: the Atlanta cardiomyopathy consortium. Congest Heart Fail. 2013;19:16–24.
16. Uppal K, Soltow QA, Strobel FH, Pittard WS, Gernert KM, Yu T, Jones DP. Xmsanalyzer: automated pipeline for improved feature detection and downstream analysis of large-scale, non-targeted metabolomics data. BMC Bioinformatics. 2013;14.
17. Go YM, Walker DI, Liang Y, Uppal K, Soltow QA, Tran V, Strobel F, Quyyumi AA, Ziegler TR, Pennell KD, et al. Reference standardization for mass spectrometry and high-resolution metabolomics applications to exposeome research. Toxicol Sci. 2015;148:531–543.
18. Yu T, Park Y, Johnson JM, Jones DP. APLCMS—adaptive processing of high-resolution LC/MS data. Bioinformatics. 2009;25:1930–1936.
19. Uppal K, Walker DI, Jones DP, xMSannotator: an R package for network-based annotation of high-resolution metabolomics data. Anal Chem. 2017;89:1063–1067.
20. Thyesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, Huber K, Plebani M, Biasucci LM, Tubaro M, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur J Heart J. 2012;33:2252–2257.
21. Jensen LJ, Lindberg S, Hoffmann S, Iversen AZ, Pedersen SH, Mogelvang R, Galatius S, Flyvbjerg A, Jensen JS, Bjerre M. Dynamic changes in stage levels and relationship with cardiac function in stemi patients. Clin Biochem. 2015;48:297–301.
22. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol). 1995;57:289–300.
23. Li S, Park Y, Duraisingham S, Strobel FH, Khan N, Soltow QA, Jones DP, Pulemendran B. Predicting network activity from high throughput metabolomics. PLoS Comput Biol. 2013;9:e1003123.
24. Smith CA, Maille GO, Want EJ, Qin C, Trauber SA, Brandon TR, Custodio DE, Abagyan R, Uziel G. METLIN: a metabolite mass spec-tral database. Ther Drug Monit. 2005;27:741–751.
25. Wishart DS, Feunang YD, Marcu A, Guo AC, Liang K, Vazquez-Frias P, Sajed T, Johnson D, Li C, Karu N, et al. HMDB 4.0: the human metabolome database for mass spectrometry and high-resolution metabolomics applications. Nucleic Acids Res. 2018;46:D608–D617.
26. Kanehisa M, Furumichi M, Tanabe M, Vishwakarma S, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45:D353–D361.
27. Schymanski EL, Jeon J, Gulde R, Fenner K, Ruff M, Singer HP, Hollender J. Identifying small molecules via high resolution mass spectrometry: communicating confidence. Environ Sci Technol. 2014;48:2097–2098.
28. Mehta RS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292.
29. Hißler-Kleiner D, Landmesser U, Drexler H. Molecular mechanisms in heart failure: focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol. 2006;48:A56–A66.
30. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. *N Engl J Med*. 2007;357:1121–1135.
31. Sabbah HN, Sharov VG, Goldstein S. Programmed cell death in the progression of heart failure. *Ann Med*. 1998;30:33–38.
32. Altamirano F, Wang ZV, Hill JA. Cardioprotection in ischaemia–reperfusion injury: novel mechanisms and clinical translation. *J Physiol*. 2015;593:3773–3788.
33. Duan Q, Yang W, Jiang D, Tao K, Dong A, Cheng H. Spermine ameliorates ischemia/reperfusion injury in cardiomyocytes via regulation of autophagy. *Am J Transl Res*. 2016;8:3976.
34. AsB Gustafsson, Gottlieb RA. Autophagy in ischemic heart disease. *Circ Res*. 2009;104:150–158.
35. Qin F, Shite J, Liang CS. Antioxidants attenuate myocyte apoptosis and improve cardiac function in CHF: association with changes in MAPK pathways. *Am J Physiol Heart Circ Physiol*. 2003;285:H822–H832.
36. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. *N Engl J Med*. 1999;341:1276–1283.
37. Zhao YJ, Xu CQ, Zhang WH, Zhang L, Bian SL, Huang Q, Sun HL, Li QF, Zhang YQ, Tian Y. Role of polyamines in myocardial ischemia/reperfusion injury and their interactions with nitric oxide. *Eur J Pharmacol*. 2007;562:236–246.
38. Schlüter K-D, Schulz R, Schreckenberg R. Arginase induction and activation during ischemia and reperfusion and functional consequences for the heart. *Front Physiol*. 2015;6:65.
39. Smajilovic S, Chattopadhyay N, Teft-Hansen J. Calcium-sensing receptor in cardiac physiology. *Open Heart Fail J*. 2010;3:11–15.
40. Cheng ML, Wang CH, Shiao MS, Liu MH, Huang YY, Huang CY, Mao CT, Lin JF, Ho HY, Yang NL. Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. *J Am Coll Cardiol*. 2015;65:1509–1520.
41. Wang CH, Cheng ML, Liu MH, Kuo LT, Shiao MS. Metabolic profile provides prognostic value better than galectin-3 in patients with heart failure. *J Cardiol*. 2017;70:92–98.
Table S1. Hazard ratio estimates for the association between BNP-N8AS strata, all-cause mortality and HF hospitalization in ICM.

| BNP-N8AS strata † | All-cause mortality* | Heart failure hospitalization* |
|-------------------|---------------------|-------------------------------|
|                   | HR (95% CI)         | P-value                       | HR (95% CI)       | P-value |
| Low-BNP Low-N8AS (n=20) | REF             | REF                           | REF               | REF     |
| High-BNP or high-N8AS (n=55) | 1.53 (0.74 – 3.16) | 0.25                          | 1.51 (0.54 – 4.18) | 0.43    |
| High-BNP and High-N8AS (n=69) | 2.14 (1.05 - 4.28)| 0.04                          | 3.44 (1.23 – 9.62) | 0.02    |

*Hazard ratios were calculated with the use of Cox regression models, adjusting for age, sex, race, creatinine, presence of diabetes, hypertension, hyperlipidemia, BMI and smoking history.

†High BNP: >100 pg/mL, High N8AS: >median
Table S2. Comparison of the baseline characteristics of ICM patients in the Discovery and Validation cohorts.

|                          | Discovery (n=154) | Validation (n=85) | P-value |
|--------------------------|------------------|------------------|---------|
| **Demographic data**     |                  |                  |         |
| Age, years               | 68.32 ± 10.50    | 60.31 ± 11.64    | <0.001  |
| Male sex                 | 117 (76.0)       | 69 (81.2)        | 0.35    |
| Black race               | 21 (13.6)        | 31 (36.5)        | <0.001  |
| **Clinical data**        |                  |                  |         |
| Diabetes                 | 72 (46.8)        | 34 (40.0)        | 0.31    |
| Hypertension             | 105 (68.2)       | 63 (74.1)        | 0.34    |
| Hyperlipidemia           | 100 (64.9)       | 58 (68.2)        | 0.61    |
| Smoking history          | 107 (69.5)       | 10 (11.8)        | <0.001  |
| BMI, kg/m²               | 28.24 ± 4.82     | 29.89 ± 6.77     | 0.05    |
| Serum creatinine, md/dL  | 1.35 ± 0.68      | 1.33 ± 0.44      | 0.79    |
| Ejection Fraction, %     | 30.31 ± 9.91     | 22.69 ± 9.19     | <0.001  |
| **Medication history**   |                  |                  |         |
| ACEi/ARB                 | 116 (75.3)       | 70 (82.4)        | 0.21    |
| BB                       | 125 (81.2)       | 82 (96.5)        | 0.001   |
| **Biomarkers**           |                  |                  |         |
| BNP, pg/mL | 325.40 [125.60, 739.38] | 247.00 [112.25, 786.25] | 0.52 |

Data are mean ± standard deviation, median (interquartile range), or N (%). ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, Beta blocker; BMI, body mass index; BNP, B-type natriuretic peptide in picograms per milliliter.
Table S3. Baseline characteristics of CAD patients with and without incident HF during follow-up in the Discovery cohort.

|                                    | CAD/No HF (n=298) | Incident HF (n=22) | P-value |
|------------------------------------|-------------------|-------------------|---------|
| **Demographic data**               |                   |                   |         |
| Age, years                         | 67.15 ± 10.63     | 71.31 ± 12.10     | 0.08    |
| Male sex                           | 218 (73.2%)       | 16 (72.7%)        | 0.96    |
| Black race                         | 34 (11.4%)        | 1 (4.5%)          | 0.32    |
| **Clinical data**                  |                   |                   |         |
| Diabetes                           | 115 (38.6%)       | 9 (40.9%)         | 0.83    |
| Hypertension                       | 212 (71.1%)       | 18 (81.8%)        | 0.28    |
| Hyperlipidemia                     | 209 (70.1%)       | 16 (72.7%)        | 0.78    |
| Smoking history                    | 198 (66.4%)       | 18 (81.8%)        | 0.14    |
| BMI, kg/m²                         | 28.74 ± 5.12      | 29.30 ± 4.58      | 0.62    |
| Serum creatinine, mg/dL            | 1.29 ± 1.31       | 1.39 ± 0.36       | 0.71    |
| Ejection Fraction, %               | 56.27 ± 6.28      | 56.95 ± 5.88      | 0.62    |
| Modified Duke CAD Index*           | 53.05 ± 26.60     | 53.37 ± 23.33     | 0.96    |
| **Medication history**             |                   |                   |         |
| ACE/ARB                            | 201 (67.4%)       | 14 (63.6%)        | 0.71    |
| BB   | 228 (76.5%) | 17 (77.3%) | 0.93 |
### Established biomarkers

| Biomarker   | Mean ± SD | Median (IQR) | P-value |
|-------------|-----------|--------------|---------|
| BNP, pg/mL  | 96.30 [45.85, 189.85] | 183.20 [68.75, 414.75] | 0.01 |
| hsTnI, pg/mL| 6.70 [3.50, 17.30]  | 9.60 [5.98, 24.85]  | 0.08 |
| hsCRP, mg/L | 3.10 [1.20, 7.50]  | 2.25 [1.15, 7.65]  | 0.77 |

*Data missing for 12.8% of subjects

Data are mean ± standard deviation, median (interquartile range), or N (%). ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, Beta blocker; BMI, body mass index; BNP, B-type natriuretic peptide in picograms per milliliter; CAD, Coronary Artery Disease; HF, Heart Failure; hsCRP, High-sensitivity C-Reactive Protein in milligrams per liter; hsTnI, High-sensitivity Troponin I in picograms per milliliter.
Table S4. Baseline characteristics of patients with NICM and ICM in the Validation cohort.

|                              | NICM (n=131) | ICM (n=85) | P-value |
|------------------------------|--------------|------------|---------|
| **Demographics**             |              |            |         |
| Age, years                   | 54.53 ± 10.98| 60.31 ± 11.64| <0.001 |
| Male sex                     | 76 (58.0)    | 69 (81.2)  | <0.001 |
| Black race                   | 67 (51.1)    | 31 (36.5)  | 0.03    |
| **Clinical data**            |              |            |         |
| Diabetes                     | 36 (27.5)    | 34 (40.0)  | 0.06    |
| Hypertension                 | 81 (61.8)    | 63 (74.1)  | 0.06    |
| Hyperlipidemia               | 52 (39.7)    | 58 (68.2)  | <0.001 |
| Smoking history              | 18 (13.8)    | 10 (11.8)  | 0.66    |
| BMI, kg/m²                   | 31.35 ± 7.89 | 29.89 ± 6.77 | 0.16    |
| Serum creatinine, mg/dL      | 1.32 ± 0.72  | 1.33 ± 0.44 | 0.89    |
| Ejection fraction, %         | 23.99 ± 11.73| 22.69 ± 9.19 | 0.37    |
| **Medication history**       |              |            |         |
| ACE/ARB                      | 104 (79.4)   | 70 (82.4)  | 0.59    |
| BB                           | 120 (91.6)   | 82 (96.5)  | 0.16    |
| **Biomarkers**               |              |            |         |
| BNP, pg/mL | 195.00 [49.00, 617.00] | 247.00 [112.25, 786.25] | 0.10 |

Data are mean ± standard deviation, median (interquartile range), or N (%). ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, Beta blocker; BMI, body mass index; BNP, B-type natriuretic peptide in picograms per milliliter; CAD, Coronary Artery Disease; EF, Ejection Fraction; HF, Heart Failure; ICM, Ischemic Cardiomyopathy; NICM, Non Ischemic Cardiomyopathy.
Table S5. Metabolites that significantly correlated (FDR q<0.01) with N8AS by global correlation mWAS.

| m/z_RT(sec)     | Spearman correlation coefficient | P-value  | FDR Q-value | HMDB Confidence* | HMDB Name                                      | HMDB ID       | Adduct   |
|-----------------|----------------------------------|----------|-------------|------------------|------------------------------------------------|--------------|----------|
| mz241.1547_t42 | 0.37                             | 1.09E-16 | 3.11E-13    | 2                | Pirbuterol                                      | HMDB15407    | M+H      |
| mz207.1105_t42 | 0.36                             | 4.27E-16 | 8.14E-13    | NA               | NA                                             | NA           | NA       |
| mz185.1285_t46 | 0.34                             | 1.88E-14 | 2.69E-11    | NA               | NA                                             | NA           | NA       |
| mz229.1547_t42 | 0.34                             | 5.02E-14 | 5.74E-11    | 3                | Several metabolite matches                      | Several matches to HMDB IDs |
| mz189.1597_t36 | 0.29                             | 6.19E-11 | 5.90E-08    | 2                | N6N6N6-Trimethyl-L-lysine                      | HMDB01325    | M+H      |
| mz            | 0.29 | 8.72E-11 | 6.46E-08 | 2   | Several metabolite matches | Several matches to HMDB IDs |
|---------------|------|----------|----------|-----|-----------------------------|-----------------------------|
| mz136.0482_t39| 0.29 | 9.05E-11 | 6.46E-08 | NA  | NA                          | NA                          |
| mz384.2738_t285| 0.29 | 1.02E-10 | 6.46E-08 | NA  | NA                          | NA                          |
| mz223.0844_t39| 0.29 | 1.79E-10 | 9.99E-08 | NA  | NA                          | NA                          |
| mz369.2824_t327| 0.29 | 1.92E-10 | 9.99E-08 | 3; 2| Several metabolite matches | Several matches to HMDB IDs |
| mz230.158_t43 | 0.28 | 2.70E-10 | 1.29E-07 | 3   | Several metabolite matches | Several matches to HMDB IDs |
| mz129.0658_t40| 0.28 | 4.65E-10 | 2.04E-07 | 2   | Several metabolite matches | Several matches to HMDB IDs |
| mz               | Retention Time | Mass / Charge | Intensity       | Formula                                      | Spectral Database  | Charge  |
|------------------|----------------|---------------|-----------------|----------------------------------------------|--------------------|---------|
| mz438.3207_t342  | 0.28           | 5.20E-10      | 2.13E-07        | NA                                           | NA                 | NA      |
| mz371.298_t347   | 0.27           | 1.21E-09      | 4.62E-07        | NA                                           | NA                 | NA      |
| mz386.2895_t308  | 0.27           | 1.98E-09      | 7.06E-07        | NA                                           | NA                 | NA      |
| mz389.3085_t325  | 0.27           | 2.75E-09      | 9.25E-07        | 3; 2 2-Hydroxymyristoylcarnitine; Methyl 2-(10-heptadecenyl)-6-hydroxybenzoate | HMDB13166; HMDB38523 | M+H[+1] |
| mz146.1175_t41   | 0.27           | 3.85E-09      | 1.22E-06        | 2 3-Dehydroxycarnitine                      | HMDB06831          | M+H     |
| mz343.2668_t308  | 0.26           | 1.20E-08      | 3.60E-06        | 3 trans-2-Dodecenoylcarnitine                | HMDB13326          | M+H[+1] |
| mz358.2577_t202  | 0.26           | 1.34E-08      | 3.84E-06        | NA                                           | NA                 | NA      |
| mz186.0186_t36   | 0.26           | 1.41E-08      | 3.84E-06        | NA                                           | NA                 | NA      |
| mz          | MZ    | Score | Area     | Match | Name                          | HMDB ID  | Charge |
|-------------|-------|-------|----------|-------|-------------------------------|----------|--------|
| mz372.3015_t347 | 0.26  | 1.74E-08 | 4.51E-06 | NA    | NA                            | NA       | NA     |
| mz344.2791_t329 | 0.25  | 2.25E-08 | 5.60E-06 | 3     | Dodecanoylcarnitine           | HMDB02250| M+H    |
| mz230.1865_t50  | 0.25  | 2.45E-08 | 5.83E-06 | NA    | NA                            | NA       | NA     |
| mz368.2795_t327 | 0.25  | 3.36E-08 | 7.69E-06 | NA    | NA                            | NA       | NA     |
| mz340.2476_t291 | 0.25  | 4.04E-08 | 8.88E-06 | NA    | NA                            | NA       | NA     |
| mz186.1317_t47  | 0.25  | 5.80E-08 | 1.23E-05 | 2     | Several metabolite matches    | Several matches to HMDB IDs |        |
| mz204.9579_t34  | 0.24  | 1.45E-07 | 2.96E-05 | NA    | NA                            | NA       | NA     |
| mz342.2635_t309 | 0.23  | 2.55E-07 | 5.04E-05 | 3     | trans-2-Dodecenoylcarnitine   | HMDB13326| M+H    |
| mz              | Charge | m/z     | Retention Time | Purity | M/Z   |ính | Name                     |HMDB ID   | Charge State |
|-----------------|--------|---------|----------------|--------|-------|----|-------------------------|----------|--------------|
| mz142.9379 t87  | 0.23   | 2.68E-07| 5.11E-05       | NA     | NA    |    | NA                      | NA       | NA           |
| mz395.2979 t346 | 0.23   | 3.61E-07| 6.66E-05       | 2      | 78-Dehydro-beta-micropteroxanthin | HMDB38506 | M+H         |
| mz115.0695 t40  | 0.23   | 3.95E-07| 7.06E-05       | NA     | NA    |    | 6-Keto-decanoylcarnitine | HMDB13202 | M+H         |
| mz330.2274 t47  | 0.23   | 4.11E-07| 7.12E-05       | 2      | 6-Keto-decanoylcarnitine         | HMDB13202 | M+H         |
| mz399.3258 t293 | 0.23   | 4.45E-07| 7.48E-05       | NA     | NA    |    | NA                      | NA       | NA           |
| mz396.3103 t359 | 0.23   | 4.77E-07| 7.80E-05       | NA     | NA    |    | NA                      | NA       | NA           |
| mz302.1955 t48  | 0.23   | 4.95E-07| 7.87E-05       | NA     | NA    |    | NA                      | NA       | NA           |
| mz185.1149 t75  | 0.23   | 5.69E-07| 8.79E-05       | NA     | NA    |    | NA                      | NA       | NA           |
| mz          | Retention | Score 1  | Score 2  | Peptide     | Metabolite Name                                      | HMDB ID         | Charge |
|------------|-----------|----------|----------|-------------|------------------------------------------------------|-----------------|--------|
| mz253.1272_t38 | 0.23      | 6.28E-07 | 9.45E-05 | 2           | Several metabolite matches                           | Several matches to HMDB IDs |          |
| mz370.2946_t347 | 0.23      | 7.13E-07 | 1.03E-04 | NA          | NA                                                   | NA              | NA     |
| mz399.3292_t376 | 0.23      | 7.23E-07 | 1.03E-04 | 3           | Trans-hexadec-2enoyl carnitine                       | HMDB06317       | M+H    |
| mz568.2331_t409 | -0.22     | 8.49E-07 | 1.18E-04 | NA          | NA                                                   | NA              | NA     |
| mz261.6174_t410 | -0.22     | 1.02E-06 | 1.38E-04 | NA          | NA                                                   | NA              | NA     |
| mz372.3102_t366 | 0.22      | 1.09E-06 | 1.45E-04 | NA          | Tetradecanoyl carnitine                              | HMDB05066       | M+H    |
| mz236.9982_t45  | 0.22      | 1.24E-06 | 1.61E-04 | NA          | NA                                                   | NA              | NA     |
| mz388.3051_t326 | 0.22      | 1.32E-06 | 1.67E-04 | 3           | 2-Hydroxymyristoylcarnitine                         | HMDB13166       | M+H    |
| m/z        | i    | Retention Time (min) | RT Error (s) | Intensity (a.u.) | Name                                                                 | Database IDs               | Charge  |
|------------|------|----------------------|--------------|------------------|----------------------------------------------------------------------|----------------------------|---------|
| mz453.3758_t410 | 0.22 | 1.44E-06             | 1.79E-04     | 2                | 23-Dihydro-phytomenadione; Phylloquinol                             | HMDB34839; HMDB60502       | M+H     |
| mz394.2946_t347 | 0.22 | 2.29E-06             | 2.75E-04     | NA               | Tetradecanoyl carnitine                                             | HMDB05066                 | M + Na  |
| mz270.9583_t42  | 0.22 | 2.31E-06             | 2.75E-04     | NA               | NA                                                                  | NA                         | NA      |
| mz315.2361_t159 | 0.21 | 2.40E-06             | 2.80E-04     | NA               | NA                                                                  | NA                         | NA      |
| mz172.0403_t39  | 0.21 | 2.47E-06             | 2.83E-04     | NA               | L-methionine                                                        | HMDB00696                 | M+Na    |
| mz1091.7035_t44 | -0.21| 2.53E-06             | 2.84E-04     | 3                | LysoPC(20:3(5Z8Z11Z)); LysoPC(20:3(8Z11Z14Z))                        | HMDB10393; HMDB10394      | 2M+H    |
| mz381.3155_t293 | 0.21 | 2.78E-06             | 3.06E-04     | NA               | NA                                                                  | NA                         | NA      |
| mz304.2119_t46  | 0.21 | 3.08E-06             | 3.32E-04     | NA               | NA                                                                  | NA                         | NA      |
| mz159.1493_t36  | 0.21 | 3.27E-06             | 3.46E-04     | NA               | NA                                                                  | NA                         | NA      |
| mz266.1217_t55   | 0.21 | 3.51E-06 | 3.61E-04 | 3; 2 | Several metabolite matches | Several matches to HMDB IDs |
|------------------|------|----------|----------|------|---------------------------|---------------------------|
| mz420.8851_t38   | 0.21 | 3.53E-06 | 3.61E-04 | NA   | NA                        | NA                        |
| mz153.066_t46    | 0.21 | 3.98E-06 | 4.00E-04 | 2    | N1-Methyl-2-pyridone-5-carboxamide; N1-Methyl-4-pyridone-3-carboxamide | HMDB04193; HMDB04194 |
| mz469.3111_t407  | -0.21| 4.34E-06 | 4.28E-04 | NA   | NA                        | NA                        |
| mz491.2935_t408  | -0.21| 4.51E-06 | 4.36E-04 | NA   | NA                        | NA                        |
| mz549.3641_t444  | -0.21| 4.58E-06 | 4.36E-04 | 3    | LysoPC(20:3(5Z8Z11Z)); LysoPC(20:3(8Z11Z14Z)) | HMDB10393; HMDB10394 |
| mz227.1251_t44   | 0.21 | 6.61E-06 | 6.20E-04 | NA   | NA                        | NA                        |
| mz398.3258_t376  | 0.2  | 7.18E-06 | 6.62E-04 | 3    | trans-Hexadec-2-enoyl carnitine | HMDB06317 | M+H |
| mz260.9725_t417   | -0.2  | 7.30E-06 | 6.63E-04 | NA     | NA     | NA     | NA     |
|-------------------|-------|----------|----------|--------|--------|--------|--------|
| mz541.3096_t414   | -0.2  | 7.41E-06 | 6.63E-04 | 3      | Several metabolite matches | Several matches to HMDB IDs | NA     |
| mz564.2914_t423   | -0.2  | 7.99E-06 | 7.03E-04 | NA     | NA     | NA     | NA     |
| mz424.3414_t384   | 0.2   | 8.17E-06 | 7.05E-04 | NA     | Linoelaidyl carnitine | HMDB06461 | M+H    |
| mz519.3272_t413   | -0.2  | 8.26E-06 | 7.05E-04 | 3      | Several metabolite matches | Several matches to HMDB IDs | NA     |
| mz174.9533_t473   | 0.2   | 8.56E-06 | 7.20E-04 | NA     | NA     | NA     | NA     |
| mz273.6277_t422   | -0.2  | 8.84E-06 | 7.33E-04 | NA     | NA     | NA     | NA     |
| mz             | rt   | m/z   | RT     | Pred MPL | Conf | MetaID | HMDB ID | Formula          | Charge | ExBuilder | Description          |
|----------------|------|-------|--------|----------|-------|--------|---------|-------------------|--------|------------|--------------------|
| mz258.1096_t428| -0.2 | 1.06E-05 | 8.64E-04 | 2        |       |        |         | Several matches   |        |            | Several metabolite matches |
| mz367.2836_t403| 0.2  | 1.11E-05 | 8.92E-04 | NA       | NA    | NA     | NA      | NA                | NA     |            | NA                 |
| mz596.3705_t453| -0.2 | 1.24E-05 | 9.85E-04 | NA       | NA    | NA     | NA      | NA                | NA     |            | NA                 |
| mz1042.6821_t433| -0.2 | 1.35E-05 | 1.05E-03 | NA       | NA    | NA     | NA      | NA                | NA     |            | NA                 |
| mz1026.66_t431 | -0.2 | 1.41E-05 | 1.09E-03 | NA       | NA    | NA     | NA      | NA                | NA     |            | NA                 |
| mz482.6125_t42 | -0.2 | 1.48E-05 | 1.13E-03 | NA       | NA    | NA     | NA      | NA                | NA     |            | NA                 |
| mz86.096_t43   | -0.2 | 1.52E-05 | 1.14E-03 | 2        |       |        |         | Piperidine         |        |            | HMDB34301          |
| mz129.0519_t37 | 0.2  | 1.53E-05 | 1.14E-03 | NA       | NA    | NA     | NA      | NA                | NA     |            | NA                 |
| mz      | r    | m/z     | Intensity | Delta Retention Time | Match | HMDB IDs              | mz       | r    | m/z     | Intensity | Delta Retention Time | Match | HMDB IDs              |
|---------|------|---------|-----------|--------------------|-------|-----------------------|----------|------|---------|-----------|--------------------|-------|-----------------------|
| mz565.309_t414 | -0.2 | 1.62E-05 | 1.18E-03  | NA                 | NA    | NA                    | mz565.309_t414 | -0.2 | 1.62E-05 | 1.18E-03  | NA                 | NA    | NA                    |
| mz144.0802_t64  | 0.2  | 1.63E-05 | 1.18E-03  | 2                  | Several metabolite matches | Several matches to HMDB IDs | mz144.0802_t64  | 0.2  | 1.63E-05 | 1.18E-03  | 2                  | Several matches to HMDB IDs | mz144.0802_t64  | 0.2  | 1.63E-05 | 1.18E-03  | 2                  | Several matches to HMDB IDs |
| mz206.0477_t109 | 0.2  | 1.65E-05 | 1.18E-03  | NA                 | NA    | NA                    | mz206.0477_t109 | 0.2  | 1.65E-05 | 1.18E-03  | NA                 | NA    | NA                    |
| mz548.3616_t445 | -0.19 | 2.07E-05 | 1.46E-03  | 3                  | LysoPC(20:3(5Z8Z11Z)); LysoPC(20:3(8Z11Z14Z)) | HMDB10393; HMDB10394 | mz548.3616_t445 | -0.19 | 2.07E-05 | 1.46E-03  | 3                  | LysoPC(20:3(5Z8Z11Z)); LysoPC(20:3(8Z11Z14Z)) | HMDB10393; HMDB10394 |
| mz572.2435_t415 | -0.19 | 2.09E-05 | 1.46E-03  | NA                 | NA    | NA                    | mz572.2435_t415 | -0.19 | 2.09E-05 | 1.46E-03  | NA                 | NA    | NA                    |
| mz384.3102_t362 | 0.19  | 2.22E-05 | 1.53E-03  | NA                 | NA    | NA                    | mz384.3102_t362 | 0.19  | 2.22E-05 | 1.53E-03  | NA                 | NA    | NA                    |
| mz286.6253_t416 | -0.19 | 2.31E-05 | 1.56E-03  | NA                 | NA    | NA                    | mz286.6253_t416 | -0.19 | 2.31E-05 | 1.56E-03  | NA                 | NA    | NA                    |
| mz521.7852_t422 | -0.19 | 2.31E-05 | 1.56E-03  | NA                 | NA    | NA                    | mz521.7852_t422 | -0.19 | 2.31E-05 | 1.56E-03  | NA                 | NA    | NA                    |
| mz          |丰度 | m/z   | p.p.b.   | 保留时间 | 共轭离子   | m/z   | p.p.b.   | 保留时间 |
|------------|-----|-------|----------|----------|-----------|-------|----------|----------|
| mz564.305_t415 | -0.19 | 2.40E-05 | 1.59E-03 | NA       | NA        | NA    | NA       | NA       |
| mz212.9996_t41 | 0.19  | 2.43E-05 | 1.60E-03 | 3        | Uric acid | HMDB00289 | M+2Na-H  |
| mz353.0548_t429 | -0.19 | 2.63E-05 | 1.71E-03 | NA       | NA        | NA    | NA       | NA       |
| mz207.1492_t43 | 0.19  | 2.76E-05 | 1.78E-03 | 2        | Agrocybenine; Monoethylglycinexylidide | HMDB41445; HMDB60656 | M+H |
| mz124.9997_t435 | -0.19 | 2.84E-05 | 1.81E-03 | NA       | NA        | NA    | NA       | NA       |
| mz246.7838_t41 | -0.19 | 3.06E-05 | 1.92E-03 | NA       | NA        | NA    | NA       | NA       |
| mz279.1427_t41 | 0.19  | 3.28E-05 | 2.04E-03 | 2        | Pentoxifylline | HMDB14944 | M+H |
| mz1041.685_t444 | -0.19 | 3.72E-05 | 2.29E-03 | NA       | NA        | NA    | NA       | NA       |
| mz216.9227_t39 | 0.19  | 3.77E-05 | 2.29E-03 | NA       | NA        | NA    | NA       | NA       |
| mz        | p-value | f-value | p-value_matched | num_matches | HMDB IDs |
|-----------|---------|---------|-----------------|-------------|----------|
| mz454.441_t449 | 0.19    | 3.93E-05 | 2.35E-03       | NA          | NA       |
| mz152.0217_t39  | 0.19    | 3.95E-05 | 2.35E-03       | NA          | NA       |
| mz148.1102_t36  | 0.19    | 4.03E-05 | 2.37E-03       | NA          | NA       |
| mz866.3046_t43  | -0.19   | 4.07E-05 | 2.37E-03       | NA          | NA       |
| mz1043.692_t447 | -0.19   | 4.16E-05 | 2.38E-03       | NA          | NA       |
| mz283.1634_t39  | 0.19    | 4.16E-05 | 2.38E-03       | NA          | NA       |
| mz819.4669_t433 | -0.19   | 4.24E-05 | 2.40E-03       | NA          | NA       |
| mz413.3051_t440 | 0.19    | 4.43E-05 | 2.48E-03       | 3           | Several metabolite matches, Several matches to HMDB IDs |
| mz          | Charge | m/z      | Intensity | Score | Metabolite                        | HMDB ID(s)                  | Adduct |
|-------------|--------|----------|-----------|-------|----------------------------------|----------------------------|--------|
| m/z180.0656_t68 | 0.19   | 4.55E-05 | 2.52E-03  | 2     | Hippurate                        | HMDB00714                  | M+H    |
| m/z170.0929_t38 | 0.19   | 4.78E-05 | 2.63E-03  | 2     | 1-Methylhistidine; 3-Methylhistidine | HMDB00001; HMDB00479        | M+H    |
| m/z582.2524_t423 | -0.19  | 4.99E-05 | 2.71E-03  | NA    | NA                               | NA                         | NA     |
| m/z219.1724_t47 | 0.19   | 5.05E-05 | 2.71E-03  | 2     | Several metabolite matches       | Several matches to HMDB IDs | NA     |
| m/z1089.6888_t43 | -0.19  | 5.07E-05 | 2.71E-03  | NA    | NA                               | NA                         | NA     |
| m/z284.1853_t45 | 0.18   | 5.19E-05 | 2.73E-03  | 2     | alpha-Hydroxymetoprolol          | HMDB60994                  | M+H    |
| m/z1025.6565_t43 | -0.18  | 5.20E-05 | 2.73E-03  | NA    | NA                               | NA                         | NA     |
| m/z1042.6924_t44 | -0.18  | 5.29E-05 | 2.75E-03  | NA    | NA                               | NA                         | NA     |
| mz          | delta | p-value | p-value | precursor | name                                                      | HMDBID | charge |
|-------------|-------|---------|---------|-----------|-----------------------------------------------------------|--------|--------|
| mz547.3486_t432 | -0.18 | 5.34E-05 | 2.75E-03 | NA        | NA                                                        | NA     | NA     |
| mz493.3111_t403 | -0.18 | 5.59E-05 | 2.85E-03 | NA        | NA                                                        | NA     | NA     |
| mz412.3056_t365 | 0.18  | 5.85E-05 | 2.94E-03 | 3         | 3-Hydroxyhexadecadienoylcarnitine                        | HMDB13335 | M+H    |
| mz259.0051_t41  | 0.18  | 5.85E-05 | 2.94E-03 | NA        | NA                                                        | NA     | NA     |
| mz578.2549_t424 | -0.18 | 6.34E-05 | 3.15E-03 | NA        | NA                                                        | NA     | NA     |
| mz584.2504_t420 | -0.18 | 6.42E-05 | 3.17E-03 | NA        | NA                                                        | NA     | NA     |
| mz144.9917_t32  | 0.18  | 6.78E-05 | 3.31E-03 | NA        | NA                                                        | NA     | NA     |
| mz366.2633_t330 | 0.18  | 6.99E-05 | 3.38E-03 | NA        | NA                                                        | NA     | NA     |
| mz            | retention time | m/z   | abundance | Charge | Peak Purity | Parent Compound | HMDB ID | Adduct | Parent Compound | HMDB ID | Adduct |
|---------------|----------------|-------|-----------|--------|-------------|-----------------|---------|--------|-----------------|---------|--------|
| mz258.2176_t43| 0.18           | 7.03E-05 | 3.38E-03  | NA     | NA          | NA              | NA      | NA     | NA              | NA      | NA     |
| mz492.3082_t408| -0.18          | 7.22E-05 | 3.44E-03  | NA     | NA          | NA              | NA      | NA     | NA              | NA      | NA     |
| mz1090.6927_t43| -0.18          | 7.48E-05 | 3.53E-03  | NA     | NA          | NA              | NA      | NA     | NA              | NA      | NA     |
| mz205.1263_t42 | 0.18           | 7.76E-05 | 3.63E-03  | NA     | NA          | NA              | NA      | NA     | NA              | NA      | NA     |
| mz204.123_t42 | 0.18           | 7.86E-05 | 3.63E-03  | 3      | L-Acetylcarnitine | HMDB00201 | M+H    |        |                 |         |        |
| mz518.3238_t413| -0.18          | 7.86E-05 | 3.63E-03  | 3      | LysoPC(18:3(6Z9Z12Z)); LysoPC(18:3(9Z12Z15Z)) | HMDB10387; HMDB10388 | M+H    |        |                 |         |        |
| mz470.2876_t416| 0.18           | 7.95E-05 | 3.64E-03  | NA     | NA          | NA              | NA      | NA     | NA              | NA      | NA     |
| mz362.7011_t41| -0.18          | 8.33E-05 | 3.78E-03  | NA     | NA          | NA              | NA      | NA     | NA              | NA      | NA     |
| mz286.2376_t468| 0.18           | 8.40E-05 | 3.78E-03  | 2      | Myristoylglycine | HMDB13250 | M+H    |        |                 |         |        |
| mz538.5741_t41 | -0.18 | 8.48E-05 | 3.79E-03 | NA | NA | NA | NA |
| mz558.2924_t432 | -0.18 | 8.67E-05 | 3.83E-03 | NA | NA | NA | NA |
| mz506.323_t416 | -0.18 | 8.80E-05 | 3.83E-03 | 2 | 20:2(11Z14Z); LysoPE(0:020:2(11Z14Z)); LysoPE(20:2(11Z14Z)0:0) | HMDB11483; HMDB11513 | M+H |
| mz1041.675_t431 | -0.18 | 8.84E-05 | 3.83E-03 | NA | NA | NA | NA |
| mz330.2633_t297 | 0.18 | 8.85E-05 | 3.83E-03 | NA | NA | NA | NA |
| mz1044.6487_t453 | -0.18 | 8.99E-05 | 3.86E-03 | NA | NA | NA | NA |
| mz795.973_t446 | -0.18 | 9.43E-05 | 4.03E-03 | NA | NA | NA | NA |
| mz302.7455_t411 | -0.18 | 9.96E-05 | 4.22E-03 | NA | NA | NA | NA |
| mz294.939_t37 | 0.18 | 1.05E-04 | 4.38E-03 | NA | NA | NA | NA |
| mz                | Charge | Elution | Intensity | RT (min) | Score | Molecule Name          | HMDB ID | Charge State |
|-------------------|--------|---------|-----------|----------|-------|-------------------------|---------|---------------|
| mz452.3727_t409   | 0.18   | 1.05E-04| 4.38E-03  | NA       | NA    | NA                      | NA      | NA            |
| mz346.863_t38     | 0.18   | 1.11E-04| 4.61E-03  | NA       | NA    | NA                      | NA      | NA            |
| mz286.9072_t38    | 0.18   | 1.14E-04| 4.70E-03  | NA       | NA    | NA                      | NA      | NA            |
| mz306.7397_t41    | -0.18  | 1.16E-04| 4.72E-03  | NA       | NA    | NA                      | NA      | NA            |
| mz818.9659_t433   | -0.18  | 1.23E-04| 4.99E-03  | NA       | NA    | NA                      | NA      | NA            |
| mz475.2436_t312   | 0.17   | 1.37E-04| 5.53E-03  | 2        | Rubraflavone B  | HMDB30629 | M+H           |
| mz161.129_t38     | 0.17   | 1.39E-04| 5.55E-03  | 2        | Isoputreanine    | HMDB06009 | M+H           |
| mz796.9789_t455   | -0.17  | 1.41E-04| 5.59E-03  | NA       | NA    | NA                      | NA      | NA            |
| mz332.2418_t118   | 0.17   | 1.45E-04| 5.67E-03  | NA       | NA    | NA                      | NA      | NA            |
| mz            | M/z     | Charge | Isotopic Abundance | Unique ID | Meta ID | Description                                      |
|--------------|---------|--------|--------------------|-----------|---------|-------------------------------------------------|
| mz206.0482   | 206.04  | 5.67E-04 | NA                 | NA        | NA      | NA                                              |
| mz280.9876   | 280.99  | 5.69E-03 | NA                 | NA        | NA      | NA                                              |
| mz292.6546   | 292.65  | 5.76E-03 | NA                 | NA        | NA      | NA                                              |
| mz272.9446   | 272.94  | 5.80E-03 | NA                 | NA        | NA      | NA                                              |
| mz422.3266   | 422.33  | 5.83E-03 | NA                 | L-palmitoyl carnitine | HMDB00222 | M+Na                                            |
| mz280.1485   | 280.15  | 6.09E-03 | NA                 | NA        | NA      | NA                                              |
| mz546.3553   | 546.36  | 6.09E-03 | 3                  | LysoPC(20:3(5Z8Z11Z)); LysoPC(20:3(8Z11Z14Z)) | HMDB10393; HMDB10394 | M+H                                            |
| mz556.8594   | 556.86  | 6.09E-03 | NA                 | NA        | NA      | NA                                              |
| mz362.9265   | 362.93  | 6.19E-03 | NA                 | NA        | NA      | NA                                              |
| mz357.2823_t327 | 0.17 | 1.70E-04 | 6.27E-03 | NA | NA | NA | NA |
| mz468.3082_t411 | -0.17 | 1.72E-04 | 6.29E-03 | NA | NA | NA | NA |
| mz234.9815_t41 | 0.17 | 1.80E-04 | 6.55E-03 | NA | NA | NA | NA |
| mz122.9245_t38 | -0.17 | 1.81E-04 | 6.56E-03 | NA | NA | NA | NA |
| mz1066.6812_t43 | -0.17 | 1.96E-04 | 7.00E-03 | NA | NA | NA | NA |
| mz133.1049_t42 | -0.17 | 1.96E-04 | 7.00E-03 | 2 | 2-Heptanethiol; Heptane-1-thiol | HMDB32303; HMDB32304 | M+H |
| mz190.9121_t38 | -0.17 | 2.03E-04 | 7.21E-03 | NA | NA | NA | NA |
| mz862.3109_t42 | -0.17 | 2.05E-04 | 7.22E-03 | NA | NA | NA | NA |
| mz          | retention | mass error | peak area | match count | matches                           | HMDB IDs                  |
|------------|-----------|------------|-----------|-------------|-----------------------------------|---------------------------|
| mz571.3583_t440 | -0.17     | 2.07E-04   | 7.22E-03  | 3           | Several metabolite matches        | Several matches to HMDB IDs |
| mz311.2032_t326 | 0.17      | 2.07E-04   | 7.22E-03  | 3           | Mestranol; Gestodene; Menaquinol  | HMDB15446; HMDB15668; HMDB60487 M+H |
| mz282.1308_t411 | -0.17     | 2.11E-04   | 7.29E-03  | NA          | NA                                | NA                        |
| mz806.965_t433  | -0.17     | 2.13E-04   | 7.29E-03  | NA          | NA                                | NA                        |
| mz1037.6556_t431 | -0.17     | 2.13E-04   | 7.29E-03  | NA          | NA                                | NA                        |
| mz392.279_t329  | 0.17      | 2.19E-04   | 7.47E-03  | NA          | NA                                | NA                        |
| mz523.802_t432  | -0.17     | 2.23E-04   | 7.53E-03  | NA          | NA                                | NA                        |
| mz594.249_t421  | -0.17     | 2.26E-04   | 7.58E-03  | 2           | 4-Hydroxy-17beta-estradiol-2-S-glutathione | HMDB60139 M+H           |
| mz         | Charge | Retention Time | Peak Area | Peak Height | Identifier | Mass | Charge | Name                                                                 | Database ID          | Adduct |
|------------|--------|----------------|-----------|-------------|------------|------|--------|----------------------------------------------------------------------|----------------------|---------|
| mz188.0706_t42 | -0.17  | 2.27E-04       | 7.58E-03  | 3           | Indoleacrylic acid; 6-Chloro-N-(1-methylethyl)-135-triazine-24-diamine | 7.58E-03 | 3      | HMDB00734; HMDB33249                                                  | M+H                 |         |
| mz302.2152_t80  | 0.17   | 2.33E-04       | 7.76E-03  | NA          | NA         | 7.76E-03 | NA     | NA                                                                 | NA                   | NA      |
| mz360.275_t248  | 0.17   | 2.36E-04       | 7.79E-03  | NA          | NA         | 7.79E-03 | NA     | NA                                                                 | NA                   | NA      |
| mz205.0972_t43  | -0.17  | 2.37E-04       | 7.79E-03  | NA          | NA         | 7.79E-03 | NA     | NA                                                                 | NA                   | NA      |
| mz987.6412_t421 | -0.17  | 2.42E-04       | 7.90E-03  | NA          | NA         | 7.90E-03 | NA     | NA                                                                 | NA                   | NA      |
| mz185.9601_t41  | 0.17   | 2.43E-04       | 7.91E-03  | NA          | NA         | 7.91E-03 | NA     | NA                                                                 | NA                   | NA      |
| mz570.3536_t439 | -0.17  | 2.46E-04       | 7.93E-03  | NA          | NA         | 7.93E-03 | NA     | NA                                                                 | NA                   | NA      |
| mz172.8514_t42  | -0.17  | 2.48E-04       | 7.98E-03  | NA          | NA         | 7.98E-03 | NA     | NA                                                                 | NA                   | NA      |
| m/z     | Width | Intensity | p-Value | Area | ID               | Class       |
|---------|-------|-----------|---------|------|------------------|-------------|
| mz559.2985_t433 | -0.17 | 2.57E-04  | 8.20E-03 | NA   | NA               | NA          |
| mz552.2605_t410  | -0.17 | 2.59E-04  | 8.20E-03 | 2    | Endoxifen O-glucuronide | HMDB60622  | M+H       |
| mz521.3422_t432  | -0.17 | 2.60E-04  | 8.20E-03 | 3    | LysoPC(18:2(9Z12Z)) | HMDB10386  | M+H [+1]  |
| mz261.1885_t49   | 0.17  | 2.68E-04  | 8.43E-03 | 3    | Hexanoylcarnitine; L-Hexanoylcarnitine | HMDB00705; HMDB00756 | M+H [+1]  |
| mz91.0538_t458   | 0.17  | 2.71E-04  | 8.48E-03 | NA   | NA               | NA          |
| mz532.2797_t420  | -0.17 | 2.77E-04  | 8.57E-03 | NA   | NA               | NA          |
| mz516.9107_t432  | -0.17 | 2.77E-04  | 8.57E-03 | NA   | NA               | NA          |
| mz329.2505_t279  | 0.17  | 2.81E-04  | 8.64E-03 | 2    | Several metabolite matches | Several matches to HMDB IDs | NA          |
| mz     | Charge | Retention Time | M+H   | M+2H  | Name                              | HMDB ID       | Charge State |
|--------|--------|----------------|-------|-------|-----------------------------------|---------------|--------------|
| mz518.2327_t433 | -0.17  | 2.85E-04       | 8.73E-03 | 2     | Pyronaridine                      | HMDB42003     | M+H          |
| mz542.3235_t415  | -0.17  | 2.91E-04       | 8.86E-03 | NA    | NA                                | NA            | NA           |
| mz438.6302_t42   | -0.17  | 2.97E-04       | 8.99E-03 | NA    | NA                                | NA            | NA           |
| mz628.2589_t421  | -0.17  | 3.06E-04       | 9.19E-03 | 2     | Tri-N-acetylchitotriose           | HMDB06698     | M+H          |
| mz132.9983_t56   | -0.17  | 3.07E-04       | 9.19E-03 | NA    | NA                                | NA            | NA           |
| mz1065.678_t432  | -0.16  | 3.16E-04       | 9.41E-03 | NA    | NA                                | NA            | NA           |
| mz274.6254_t420  | -0.16  | 3.20E-04       | 9.44E-03 | 2     | Darunavir                         | HMDB15393     | M+2H         |
| mz860.3134_t43   | -0.16  | 3.20E-04       | 9.44E-03 | NA    | NA                                | NA            | NA           |
| mz186.1123_t43   | 0.16   | 3.24E-04       | 9.46E-03 | 2     | Pseudoecgonine; Ecgonine         | HMDB06348; HMDB06548 | M+H         |
| mz | m/z | delta PPM | P1-PPM | P2-PPM | Name | HMDB ID | Charge | Isotopic Formula |
|----|-----|----------|--------|--------|------|---------|--------|-----------------|
| mz273.608_t428 | 273.923 | -0.16 | 3.24E-04 | 9.46E-03 | NA | NA | NA | NA |
| mz546.3455_t432 | 546.501 | -0.16 | 3.31E-04 | 9.56E-03 | NA | NA | NA | NA |
| mz153.127_t77 | 153.127 | 0.16 | 3.31E-04 | 9.56E-03 | 2 | Several metabolite matches | Several matches to HMDB IDs |
| mz208.0393_t33 | 208.039 | 0.16 | 3.34E-04 | 9.59E-03 | NA | NA | NA | NA |
| mz192.0739_t36 | 192.074 | 0.16 | 3.36E-04 | 9.59E-03 | NA | NA | NA | NA |
| mz352.8976_t38 | 352.898 | 0.16 | 3.37E-04 | 9.59E-03 | NA | NA | NA | NA |
| mz226.9516_t37 | 226.952 | 0.16 | 3.42E-04 | 9.67E-03 | 2 | 25-Dichloro-4-oxohex-2-enedioate | HMDB60363 | M+H |
| mz104.1068_t430 | 104.107 | -0.16 | 3.47E-04 | 9.78E-03 | 2 | Neurine | HMDB31259 | M+H |
| mz400.3414_t398 | 0.16  | 3.54E-04 | 9.92E-03 | 3 | L-Palmitoylcarnitine | HMDB00222 | M+H |

HMDB ID, Human Metabolome Database Identification; m/z, mass-to-charge ratio; M+H, Hydrogen adduct; M+Na, Sodium adduct; RT, Retention time in seconds; NA, Not Annotated in HMDB

*Note(s):

1) Metabolite identification levels are adapted from the criteria proposed by Schymanski et al.:
   a. Level 1 confirmed by MS/MS and co-elution with authentic standards;
   b. Level 2 confirmed by MS/MS and matches with online databases or in-silico predicted spectra
   c. Level 3 confirmed by MS/MS at the chemical class level, but no evidence for a specific metabolite
   d. Level 4 computationally assigned annotation using xMSannotator (medium or high confidence)
   e. Level 5 accurate mass match